Bivalent RBD-based ARVAC-CG vaccine
/ National University of San Martin, National Scientific and Technical Research Council, Pablo Cassara
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 22, 2023
ARVAC-F2/3-002: ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
(clinicaltrials.gov)
- P2/3 | N=2014 | Completed | Sponsor: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
September 28, 2023
ARVAC-F2/3-002: ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
(clinicaltrials.gov)
- P2/3 | N=2014 | Active, not recruiting | Sponsor: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 02, 2023
ARVAC-F2/3-002: ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19)
(clinicaltrials.gov)
- P2/3 | N=2014 | Recruiting | Sponsor: Mónica Edith Lombardo
New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1